Wingtech Technology: Court upholds interim measures against Nexperia

Wingtech Technology: Court upholds interim measures against Nexperia

By Our Reporter

AMSTERDAM (CONVERSEER) – Wingtech Technology disclosed a progress announcement on the operation and management of its subsidiary. Regarding the hearing and core issues scheduled for January 14, 2026, the Corporate Court made a ruling on February 11, 2026 (Netherlands time).

According to an announcement, on January 14, the Corporate Court held a public hearing regarding the disputes involving Nexperia. The core issues were whether to launch an investigation into the allegations made by Nexperia’s European management and whether to rescind the temporary measures previously taken by the court, which had temporarily restricted the company’s control over Nexperia. No ruling was made at the public hearing.

After hearing the case, the Corporate Court approved the application to initiate a formal investigation, expanding the scope of the investigation to include the conduct of Nexperia’s local management.

The court also ruled that all previously issued interim measures, including restrictions on the positions of certain individuals and shareholder rights, would remain in effect during the investigation, but the trustee could not dispose of the shares during this period.

According to the ruling, two independent investigators appointed by the court will subsequently conduct the investigation.

The announcement indicates that the Corporate Court’s ruling upholds the interim measures taken against Nexperia since October 2025. During the Corporate Court’s investigation, the company’s control over Nexperia remains restricted, and the investigation period is uncertain. Investors are advised to be aware of the investment risks.

Wingtech Technology stated that since the control of its relevant subsidiaries was restricted in October 2025, the company has been striving to maintain stable operation in accordance with relevant Chinese laws and regulations.

The company will continue to exhaust all legal means to restore its complete control over Nexperia and protect the rights and interests of investors.

Share this with others: